Literature DB >> 2406032

Sensitivity of parasites to free radical damage by antiparasitic drugs.

R Docampo1.   

Abstract

Over the last few years a remarkable progress has been made in the understanding of parasites biochemistry, molecular biology, and immunology. This progress is especially encouraging in that emphasis on drug development is shifting from random screening towards a more rational approach. A number of peculiar aspects characteristic of parasites which are not present in other organisms and that might be exploitable for the design of specific agents have been described recently. One of these aspects is their deficiency in defense mechanisms against oxygen toxicity. Catalase is absent in many parasites. Distinct superoxide dismutases have been detected and specific inhibitors of these enzymes have been investigated. Glutathione is absent in some anaerobic protozoa. Peroxidase and reductase activities dependent on a glutathione-spermidine cofactor termed trypanothione have been detected in several trypanosomatids and apparently replace the glutathione peroxidase-glutathione reductase system of other eukaryotic cells. Free radical intermediates have been shown to be involved in the reaction of enzymes present in anaerobic protozoa. In addition, a number of antiparasitic agents have been shown to exert their actions through a free radical metabolism: nitro compounds used against trypanosomatids, anaerobic protozoa and helminths; crystal violet used in blood banks to prevent blood transmission of Chagas' disease; the antimalarial primaquine, chloroquinine, and quinhasou; and quinones active in vitro and in vivo against different parasites.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2406032     DOI: 10.1016/0009-2797(90)90106-w

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  29 in total

1.  Deletion of the Trypanosoma brucei superoxide dismutase gene sodb1 increases sensitivity to nifurtimox and benznidazole.

Authors:  S Radhika Prathalingham; Shane R Wilkinson; David Horn; John M Kelly
Journal:  Antimicrob Agents Chemother       Date:  2006-12-04       Impact factor: 5.191

2.  Preparation, crystallization and preliminary crystallographic analysis of old yellow enzyme from Trypanosoma cruzi.

Authors:  Shigeru Sugiyama; Keiji Tokuoka; Nahoko Uchiyama; Naoki Okamoto; Yousuke Okano; Hiroyoshi Matsumura; Koji Inaka; Yoshihiro Urade; Tsuyoshi Inoue
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2007-09-29

3.  Biochemical characterization of a trypanosome enzyme with glutathione-dependent peroxidase activity.

Authors:  S R Wilkinson; D J Meyer; J M Kelly
Journal:  Biochem J       Date:  2000-12-15       Impact factor: 3.857

4.  Benznidazole, a drug employed in the treatment of Chagas' disease, down-regulates the synthesis of nitrite and cytokines by murine stimulated macrophages.

Authors:  S Revelli; C Le Page; E Piaggio; J Wietzerbin; O Bottasso
Journal:  Clin Exp Immunol       Date:  1999-11       Impact factor: 4.330

5.  A clinical adverse drug reaction prediction model for patients with chagas disease treated with benznidazole.

Authors:  Gilberto Marcelo Sperandio da Silva; Mauro Felippe Felix Mediano; Pedro Emmanuel Alvarenga Americano do Brasil; Mayara da Costa Chambela; Joyce Almeida da Silva; Andrea Silvestre de Sousa; Sergio Salles Xavier; Andrea Rodrigues da Costa; Roberto Magalhães Saraiva; Alejandro Marcel Hasslocher-Moreno
Journal:  Antimicrob Agents Chemother       Date:  2014-08-11       Impact factor: 5.191

6.  Novel 3-nitro-1H-1,2,4-triazole-based amides and sulfonamides as potential antitrypanosomal agents.

Authors:  Maria V Papadopoulou; William D Bloomer; Howard S Rosenzweig; Eric Chatelain; Marcel Kaiser; Shane R Wilkinson; Caroline McKenzie; Jean-Robert Ioset
Journal:  J Med Chem       Date:  2012-05-23       Impact factor: 7.446

7.  Activity of the new triazole derivative albaconazole against Trypanosoma (Schizotrypanum) cruzi in dog hosts.

Authors:  Paulo Marcos da Matta Guedes; Julio A Urbina; Marta de Lana; Luis C C Afonso; Vanja M Veloso; Washington L Tafuri; George L L Machado-Coelho; Egler Chiari; Maria Terezinha Bahia
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

8.  CYP51: A major drug target in the cytochrome P450 superfamily.

Authors:  Galina I Lepesheva; Tatyana Y Hargrove; Yuliya Kleshchenko; W David Nes; Fernando Villalta; Michael R Waterman
Journal:  Lipids       Date:  2008-09-04       Impact factor: 1.880

9.  A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes.

Authors:  Shane R Wilkinson; Martin C Taylor; David Horn; John M Kelly; Ian Cheeseman
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-26       Impact factor: 11.205

10.  Purification of glutathionylspermidine and trypanothione synthetases from Crithidia fasciculata.

Authors:  K Smith; K Nadeau; M Bradley; C Walsh; A H Fairlamb
Journal:  Protein Sci       Date:  1992-07       Impact factor: 6.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.